Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
146.00    -6.80 (-4.45%)
Bid:
146.00
Ask:
153.40
Spread: 7.40 (5.068%)
Market Cap: £874.50m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

Trading Statement

24 Jun 2015 07:00

RNS Number : 0217R
Elementis PLC
24 June 2015
 



Elementis plc - Trading update

 

Elementis plc (ELM.L, the "Company" or the "Group"), the Global Specialty Chemicals Company, today issues a trading update ahead of its interim results for the half year ending 30 June 2015, which will be announced on 28 July 2015.

 

Specialty Products continues to make solid progress in terms of leveraging its strong market positions and geographic diversity, and developing new and innovative products to solve our customers' formulary challenges. Market share and contribution margins have remained stable and trading in the first half of the year is anticipated to be in line with management's expectations in most of our key markets. However, temporary market dynamics experienced in the second quarter of the year will most likely negatively influence our full year result.

 

· As recent commentary from the oil sector confirms, there has been a further significant reduction in oil projects in North America and therefore drilling activity has been further curtailed. As a result, we now expect our sales of additives for the first half and the year as a whole to the oilfield drilling market to be at least 30 per cent lower than the previous year, driven by lower volumes.

 

· In coatings additives, the Group continues to make good progress in North America, where the uptake of the new additives line for decorative coatings from our New Martinsville facility is continuing to gain traction with customers. Sales to Latin America have also been robust, based on synergy projects from the previously acquired Watercryl business. In Europe, where underlying economic activity still remains subdued, Group sales for the first half of the year, on a constant currency basis, are expected to be ahead of the same period last year. However, additives sales in China have experienced a reduction in demand during the second quarter of the year and, while the Group still expects sales to be ahead of prior year for the year as a whole, Asia Pacific sales in the first half will be similar to the same period last year. Consequently, overall sales of coatings additives for the first six months of the year, on a constant currency basis, are expected to be at a similar level to the same period last year.

 

· In personal care, the business continues to expand through new product sales and investments into new geographies. However, sales in Latin America have been impacted by significant local currency weakness. This has resulted in the business opting to cease supplying to a number of applications where returns have fallen below an acceptable threshold. The business is taking decisive action to address this competitive dynamic and market share gains from new product introductions have helped to offset the Latin America shortfall. Therefore, sales for the first half will be similar to the strong 2014 first half results. Additionally, positive trends in other markets and geographies mean that full year sales, on a constant currency basis, are expected to be ahead of the previous year.

 

In Chromium, the market trends outlined in the Group's Interim Management Statement in April have continued through the balance of the first half of the year. As such, management expects the operating profit for the full year to be in line with the stated strategy for the business of "stable earnings and cash flow" and the first half result to be similar to the same period last year.

 

The Group's balance sheet remains in a strong position and is expected to show a net cash position at the end of the current year. While the Group remains confident in continuing to make progress in the medium term, the cumulative impact of short term issues arising during the second quarter, as described above, is that earnings per share for the full year are anticipated to be below the current range of market expectations.

 

 

ENDS

 

Enquiries:

Elementis + 44 (0) 207 408 9300

David Dutro, Chief Executive

Brian Taylorson, Finance Director

  

FTI Consulting

 

 

+ 44 (0) 203 727 1000

Deborah Scott

Matthew Cole

  

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFJMPTMBATBIA
Date   Source Headline
16th Jan 20251:45 pmRNSHolding(s) in Company
2nd Jan 202510:06 amRNSTotal Voting Rights
24th Dec 20247:00 amRNSDirectorate Change
9th Dec 20245:05 pmRNSDirector/PDMR Shareholding
2nd Dec 202410:06 amRNSTotal Voting Rights
18th Nov 20247:00 amRNSChief Executive Succession
1st Nov 20249:54 amRNSTotal Voting Rights
29th Oct 20247:00 amRNSThird Quarter Trading Update
11th Oct 202411:18 amRNSDirector/PDMR Shareholding
17th Sep 20248:50 amRNSDirector/PDMR Shareholding
2nd Sep 20249:31 amRNSBlock listing Interim Review
23rd Aug 202410:31 amRNSHolding(s) in Company
14th Aug 202410:53 amRNSAdditional Listing
9th Aug 20242:43 pmRNSHolding(s) in Company
2nd Aug 20245:44 pmRNSHolding(s) in Company
1st Aug 20243:10 pmRNSCorrection of dividend record date
1st Aug 20247:00 amRNSHalf-year Report
15th Jul 202410:59 amRNSHolding(s) in Company
30th May 202412:52 pmRNSDirector/PDMR Shareholding
29th May 20241:07 pmRNSDirector Declaration
8th May 202411:08 amRNSDirector/PDMR Shareholding
3rd May 202411:46 amRNSHolding(s) in Company
1st May 202410:06 amRNSTotal Voting Rights
30th Apr 202411:36 amRNSResult of AGM
30th Apr 20247:00 amRNSFirst quarter trading update
29th Apr 202412:13 pmRNSResponse to open letter from Gatemore
12th Apr 202411:33 amRNSDirector/PDMR Shareholding
12th Apr 202411:28 amRNSDirector/PDMR Shareholding
9th Apr 20246:04 pmRNSDirector/PDMR Shareholding
26th Mar 20244:07 pmRNSAnnual Financial Report & Notice of AGM
19th Mar 20243:02 pmRNSAdditional Listing
15th Mar 20241:00 pmRNSDirectorate Change
12th Mar 20244:38 pmRNSDirector/PDMR Shareholding
12th Mar 20244:33 pmRNSDirector/PDMR Shareholding
8th Mar 20245:56 pmRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSDirectorate changes
7th Mar 20247:00 amRNSPreliminary results year ended 31 December 2023
1st Mar 20249:30 amRNSBlock listing Interim Review
18th Jan 20247:00 amRNSTrading Update
2nd Jan 20249:45 amRNSTotal Voting Rights
1st Dec 202310:46 amRNSTotal Voting Rights
30th Nov 20239:38 amRNSDirector/PDMR Shareholding
14th Nov 20237:00 amRNS2023 Capital Markets Day
1st Nov 20239:46 amRNSTotal Voting Rights
31st Oct 20237:00 amRNSThird Quarter Trading Update
2nd Oct 20239:34 amRNSTotal Voting Rights
20th Sep 202312:09 pmRNSResponse to open letter from Franklin Templeton
12th Sep 20233:13 pmRNSDirector Declaration
8th Sep 20239:30 amRNSHolding(s) in Company
1st Sep 20239:49 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.